Orexo AB (ORX.ST)
26 May 2017
* Says guidance issued in connection with full year report 2016 confirmed Source text for Eikon: Further company coverage: (Stockholm Newsroom)
* Orexo commences patent infringement litigation against Actavis for their generic versions of Suboxone® and Subutex® tablets in the U.S.
* Says has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59 Source text for Eikon: Further company coverage: (Stockholm Newsroom)
* Q4 net earnings msek 33.3 (-51.8) Source text for Eikon: Further company coverage: (Stockholm Newsroom)